Aytu BioPharma, Inc. Nasdaq: AYTU

June 2023

Forward Looking Statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company's plans relating to the Company's overall financial and operational performance, the Company's commercial performance, regulatory status, reimbursement status, and other factors affecting their commercial uptake, clinical development and commercialization of the Company's current and future development assets, the anticipated start dates, durations and completion dates, as well as the potential future results of the Company's ongoing and future clinical trials, the anticipated designs of the Company's future clinical trials, and the anticipated future regulatory submissions, potential adverse changes to the Company's financial position or business plans, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of the Company's products, risks related to the ongoing COVID-19 pandemic and its impact on the Company's operations, the Company's ability to effectively integrate operations and manage integration costs following the Company's recent acquisitions, the Company's partners performing their required activities, the Company's anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaboration. Additional risks are described in ''Risk Factors'' in Part I, Item 1A of Aytu's most recent Annual Report on Form 10-K and in the other reports and documents it files with the Securities and Exchange Commission.

2

Company Overview

Commercial stage pharmaceutical company providing ADHD and pediatric-focused prescription drugs and cost-effective health solutions.

Strong Revenue Growth

  • YTD FY 2023 (Mar) total net revenue increased 10.8% to $76.7 million from $69.2 million in year ago period.
  • FY 2022 (Jun) total net revenue increased 47% to $96.7 million from $65.6 million in FY 2021.
  • FY 2022 (Jun) Rx Segment net revenue was $61.1 million, compared to $32.7 million last year, growth of 87%.

Positive Adjusted EBITDA for Rx Segment

  • YTD FY 2023 (Mar) Rx Segment Adjusted EBITDA was a positive $1.1 million.
  • Pipeline R&D, which contributed a
    $(401,000) to Adjusted EBITDA during Q3 2023 (Mar) has since been suspended and continues to tail off.
  • Strong prescription trends across ADHD and pediatric portfolios driving revenue growth

Market Dynamics and

Company Growth Drivers

  • Shortages of Adderall XR generics continued into 2023 and expanded to include generic Concerta, presenting an opportunity for Adzenys XR-ODT and Cotempla XR-ODT which are bioequivalent to Adderall XR and methylphenidate ER.
  • Aytu RxConnect, a best-in-class patient access program that enables affordable, predictable, hassle-free patient access to Aytu Rx products to drive patient adherence and increased pull-through of Rx brands.

3

Strong

Revenue

Growth

$ in Millions

$100

$90

$80

$70

$60

$50

$40

$30

$20

$10

$0

Revenue

$96.7

June 30 Fiscal Year-End

$35.5

$65.6

$33.0

$27.6

$61.1

$10.4

$32.7

$17.2

2020

2021

2022

Prescription

Consumer Health

4

Strategic Realignment to

Focus on Commercial

Operations

Post this shift, Aytu generated positive Adjusted

EBITDA during 2 of its 3 quarters in FY 2023

  • YTD 2023 (Q3 Mar. 2023) Rx Adjusted EBITDA was positive $1.1M
  • On October 13th, 2022, Aytu announced a strategic shift to focus corporate resources on commercial operations and indefinitely suspended all clinical development programs.
  • This shift primarily impacts the AR101/enzastaurin clinical program for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).
  • Goal to generate positive Adjusted EBITDA
  • Projected to save >$20.0 million over three years

o Expected to significantly reduce cash burn

  • $19.2 million cash on hand as of March 31, 2023

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Aytu Biopharma Inc. published this content on 06 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 June 2023 07:25:07 UTC.